Asset type Domestic Equity Sector

KODEX Biotech(244580)

KODEX Biotech ETF invests in stocks of FnGuide Bio Index composed of both KOSPI and KOSDAQ stocks related to biotech industry.

  • Current Price


    down 285 (-3.61%)

  • iNAV


    down 256 (-3.26%)

  • Trading Volume


* Last data obtained
Quotes delayed at least 20 minutes.Market data provided by KOSCOM.

*as of

Benchmark Index

FnGuide Bio Index

The FnGuide Bio Index is designed to capture the performance of stocks related to the Biotech industry. Constituents are chosen among MKF2000 Medical Industry stocks, and must satisfy market capitalization and liquidity standards.

View index information in detail
Key Facts
  • Net Assets
    117 (billion)
  • Inception Date
    May 13, 2016
  • Gross Expense
    (AP : 0.020%, Manager fee : 0.390%, Trustee Fee : 0.020%, General Administrator Fee : 0.020%)
  • Dividend
    Quarterly and the last Business Day of fiscal year dividend distribution, only if applicable. (Record date : last Business Day of January, April, July, and October, and fiscal year)
  • Base Currency
  • General
    Shinhan Aitas
  • Trustee
    KB Bank
  • Related
  • Carefully consider the Funds' investment objectives, risk factors, and charges and expenses before investing.
  • Collective investment schemes are not insured by the Korea Deposit Insurance Corporation.
  • The performance quoted represents past performance and does not guarantee future results.
  • Investment return and principal value will fluctuate, so you may have a gain or loss when shares are sold.
  • Current performance may be lower or higher than the performance quoted.
  • This information is not warranted to be accurate, complete, or timely.
  • Neither KOSCOM nor Samsung Asset Management is responsible for any damages or losses arising from any use of the information on this website.
  • This website is made in the Korean language, and if there shall arise any conflict between the Korean version and any translation thereof, including this -English translation, the Korean version shall prevail.